Fair Value Calculator Fair Value Calculator
EN DE

1222 (1222) Fair Value & Analysis

Industrials · Market cap HK$298M

1 1222 1222 · HK
PriceHK$0.0220
Fair ValueHK$0.0222
Upside+0.8%
Quality53/100
Evidence: Low Range HK$0.0203 – HK$0.0241

Fair value as of: Jul 2, 2026

From 7 valuation models · updated today

Share price +4.8% over the past month.

Price vs Fair Value (12 months)

HK$0.0300 HK$0.0190 Fair Value HK$0.0222 Jun 2025 Jun 2026

12‑month range HK$0.0190 – HK$0.0300 · fair‑value band HK$0.0203 – HK$0.0241 · the HK$0.0220 price screens below the HK$0.0222 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1222 (1222) currently trades at HK$0.0220, while our model-based Fair Value estimate is HK$0.0222 — implying the stock looks roughly 0.8% undervalued today. We read business quality at 53/100 (solid quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

Over the trailing twelve months, 1222 generated revenue of HK$2.7B at a net margin of -50.1%. Revenue declined 1.8% year over year. It earns a return on equity of -25.5%. Net debt stands at HK$3.2B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$2.7B
Revenue growth (YoY) -1.8%
Net margin -50.1%
Return on equity -25.5%
Free cash flow HK$1.1B FY2025
Operating margin -10.4%
More key figures
EPS growth (YoY) -25.6%
Net debt HK$3.2B FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

1222 reported revenue of HK$2.6B in FY2026 versus HK$1.9B in FY2022, a compound +9.1%/yr. Reported net income was −HK$804M in FY2026.

Revenue +9.1%/yr
FY22 HK$1.9B
FY23 HK$3.6B
FY24 HK$2.0B
FY25 HK$2.7B
FY26 HK$2.6B
Net income
FY22 −HK$305M
FY23 HK$12.8M
FY24 −HK$754M
FY25 −HK$922M
FY26 −HK$804M

Is 1222 fairly valued? → Check now

Similar stocks

6 more Conglomerates stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
Honeywell International Inc HON C$25.91 C$8.49 -67%
Hitachi, Ltd HTHIY $30.11 $31.31 +4%
CITIC Limited 0267 HK$13.62 HK$22.20 +63%
0019 0019 HK$81.70 HK$13.77 -83%
CK Hutchison Holdings 0001 HK$66.25 HK$118.82 +79%
SK Inc 034730 625,000 KRW 390,279 KRW -38%

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 1222 (1222) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$0.0222 versus a price of HK$0.0220 — about +1% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 1222?
Our model-based fair value for 1222 is HK$0.0222 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.0220.
What is the quality score of 1222?
1222 has a Quality Score of 53/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 1222 (1222)?
1222 reported trailing-twelve-month revenue of about HK$2.7B (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 1222?
The net profit margin of 1222 is about -50.1%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.